Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies by Woyach, Jennifer, Stephens, Deborah M., Flinn, Ian W., Bhat, Seema A., Savage, Ronald E., Chai, Feng, Eathiraj, Sudharshan, Granlund, Lindsey, Szuszkiewicz, Lyndsey A., Schwartz, Brian, Byrd, John C.

Get full text

A Phase 1 Dose Escalation Study of ARQ 531 in Selected Patients with Relapsed or Refractory Hematologic Malignancies by Woyach, Jennifer A., Flinn, Ian W., Stephens, Deborah M., Awan, Farrukh T., Rogers, Kerry A., Reiff, Sean D., Savage, Ron E., Eathiraj, Sudharshan, Szuszkiewicz, Lyndsey A., Tith, Kate, Byrd, John C.

Get full text

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma by Woyach, Jennifer A, Stephens, Deborah M, Flinn, Ian W, Bhat, Seema A, Savage, Ronald E, Chai, Feng, Eathiraj, Sudharshan, Reiff, Sean D, Muhowski, Elizabeth M, Granlund, Lindsey, Szuszkiewicz, Lyndsey, Wang, Wayne, Schwartz, Brian, Ghori, Razi, Farooqui, Mohammed Z H, Byrd, John C

Get full text